UBP 310 is primarily used in neuroscience research as a selective antagonist for kainate receptors, specifically targeting GluK1-containing receptors. It is a valuable tool for studying the role of these receptors in synaptic transmission, plasticity, and neurological disorders. Researchers utilize UBP 310 to investigate conditions such as epilepsy, chronic pain, and neurodegenerative diseases, where kainate receptors are implicated. Its selectivity allows for precise modulation of GluK1 activity, aiding in the understanding of receptor function and potential therapeutic targets. Additionally, UBP 310 is employed in electrophysiological experiments to dissect the contributions of kainate receptors in neural circuits.